Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06528210
Title	Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
Recruitment	Recruiting
Gender	male
Phase	Phase II
Variant Requirements	No
Sponsors	OHSU Knight Cancer Institute
Indications	prostate adenocarcinoma
Therapies	Bicalutamide + Leuprolide + Pembrolizumab Bicalutamide + Goserelin + Pembrolizumab Bicalutamide + Degarelix + Pembrolizumab Bicalutamide + Pembrolizumab + Triptorelin Bicalutamide + Pembrolizumab + Relugolix
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 1 of 1 entries

Facility	Status	City	State	Zip	Country	Details
OHSU Knight Cancer Institute	RECRUITING	Portland	Oregon	97239	United States	Details

Showing 1 to 1 of 1 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field